Cardiovascular Risk, Genetics, Obesity and Obesity-related Medical Conditions
Conditions
Brief summary
experimental study with analysis on tissues. This study aims to study cardiometabolic risk from a genetic, clinical, instrumental and laboratory point of view in a population of subjects with obesity.
Detailed description
Compared to normal clinical practice, if you decide to participate in the study you will be asked to: 1. allow the collection of an additional study-specific amount of blood as part of a blood sample already provided for by clinical practice during the dietetic visit; The sample will be used to perform the genetic and laboratory analyses required by the study. 2. Undergo an additional study-specific visit within one month of the dietetic visit. will be subjected to the measurement of the degree of vascular aging and the evaluation of the health of his/her arteries, through non-invasive examinations.
Interventions
None listed
Sponsors
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* • Age \> 18 years * BMI \> 30 Kg/m2 * In primary prevention for cardiovascular disease * Ability to communicate, make themselves understood and adhere to study-specific procedures * Willingness to participate in the study and obtain informed consent
Exclusion criteria
* Patients already enrolled by the Research Units involved in the enrolment * Glycated hemoglobin level \> 55 mmol/L * Patients suffering from obesity secondary to endocrinological diseases or iatrogenic causes * Patients with heterozygous Familial Hypercholesterolemia (Dutch Lipid Score - DLS\>8) * Patients suffering from hypercholesterolemia secondary to lipid or iatrogenic extra-metabolic pathologies * Patients suffering from systemic inflammatory or oncological diseases * Patients on active treatment with GLP-1 analogues * Pregnancy and breastfeeding * Any medical or surgical condition that makes the patient's adherence to the study protocol complex or inconsistent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| cycle threshold miRNAs | at baseline | Study of the expression profile of specific circulating miRNAs |
| Presence/absence of the loss-of-function HMGA1 allelic variant (rs146052672) | baseline | search for variants of the HMGA1 gene |
| NGS sequencing of the genes: MC4R, LEP, LEPR, POMC, PCSK1, ADRA2, AGPAT2, HIF1A, HMGA2, HMGB1, INSR, PEPCK, GLUT/SGLT glucose transporters. | baseline | NGS expression of the genes: MC4R, LEP, LEPR, POMC, PCSK1, ADRA2, AGPAT2, HIF1A, HMGA2, HMGB1, INSR, PEPCK, GLUT/SGLT glucose transporters. |
| Insulinemia (µU/mL) | baseline | Levels of haematic insulin |
| C-peptide (nmol/L) | baseline | Levels of haematic of C-peptide |
| thyrotropin (nmol/L) | baseline | Levels of haematic of thyrotropin |
| HMGA1 protein assay | baseline | Levels of haematic HMGA1 protein |
Countries
Italy
Contacts
Primary ContactMaria Letizia Petroni, MD
Outcome results
None listed